Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:12 AM
Ignite Modification Date:
2025-12-25 @ 2:12 AM
NCT ID:
NCT05380960
Brief Summary:
"The objective of this study is to evaluate the blood coagulability state in patients with COPD admitted at Assiut University Hospital"
Detailed Description:
Chronic Obstructive Pulmonary Disease (COPD) is a chronic debilitating lung disease with a high prevalence of approximately 380 million cases worldwide \[1\]. It is currently the third leading cause of death, responsible for approximately 6% of the world's total deaths (approximately 3.3 million annually) \[2\]. In addition to the known devastating respiratory consequences, a large number of studies support the hypothesis that COPD increases the risk for both venous thromboembolism (VTE) and cardiovascular disease (CVD) Although the observed association of COPD with CVD and VTE can be partially explained by comorbidities and shared risk factors, there is strong evidence that COPD increases the risk for cardiovascular morbidity and mortality independently of age, gender, and smoking history \[3,4\]. It is of note that up to 63.5% of patients with COPD die of comorbid circulatory system diseases \[5\].
Increased thrombin formation \[6\] , reflected by elevated thrombin-antithrombin com- plexes \[7\] , tissue factor procoagulant activity \[8\] and activated factor XI \[9\] , increased d-dimers \[10\] , and FI \[11\] , FII and FX \[12\] levels in the serum of COPD patients support the theory that a hypercoagulable state occurs in patients with COPD and might contribute to the incidence of atherothrombotic events and VTE, increasing disease related morbidity and mortality.
Potential pathways illustrating pathogenetic mechanisms of increased risk of CVD and VTE in COPD are imprecise. Evidence illustrates four possible synergistic mechanisms: systemic inflammation \[13\], platelet activation \[14\] , oxidative stress \[15\], and hypoxia, either sustained in severe COPD or intermittent during exercise and sleep \[16,17\]
Study:
NCT05380960
Study Brief:
Protocol Section:
NCT05380960